Observational studyBreast cancer research and treatment2026
Real-world treatment patterns and clinical outcomes in patients with emerging estrogen receptor 1 (ESR1)-mutated ER+ metastatic breast cancer in the U.S., 2018-2024.
Observational study in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeClinical studies have highlighted the potential utility of monitoring for Estrogen receptor alpha 1 (ESR1) mutation (m) (ESR1m) emergence during first-line therapy (1L) for metastatic breast cancer (mBC). However, less is known about the real-world practice for patients with emergent ESR1m before progression and their outcomes. This study aimed to characterize real-world treatment patterns among patients with mBC who underwent ESR1m mutation testing during first-line (1L) therapy, and to evaluate the association between ESR1m detection during 1L and clinical outcomes.
methodsThis retrospective, observational cohort study used the US-based, deidentified Flatiron Health Research Database and included patients diagnosed with ER+/human epidermal growth factor receptor 2-negative (HER2-) metastatic BC between 2018 and June 2024. rwOS and rwPFS were estimated using the Kaplan-Meier methodology and compared after propensity score matching. Clinical outcomes were evaluated from the time of first ESR1 test during 1L therapy to minimize time-related bias.
results7772 patients who initiated 1L therapy were included. Treatment patterns in 1L were comparable between patients with (n = 240) and without (n = 1095) ESR1m detected during 1L. Among patients tested for ESR1m mutations during 1L, detection of ESR1m was associated with significantly shorter rwPFS and OS from the time of testing, both before and after propensity score matching (rwPFS hazard ratio [HR] 0.68 [95%CI: 0.48-0.96], rwOS HR: 0.58 [95%CI: 0.36-0.95]).
conclusionsDetection of ESR1m during 1L was associated with poorer clinical outcomes. These findings highlight the clinical relevance of ESR1m emergence prior to progression and underscore the need for strategies to better identify and manage patients with emerging endocrine resistance. CLINICAL TRIAL: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.